A Nature paper shows ProteinMPNN redesigns of botulinum proteases make better starting points for phage-assisted continuous evolution than wild-type enzymes. Across side-by-side campaigns, AI-stabilized starts yielded higher activity and unlocked mutations that failed in natural backgrounds. When both lineages were steered to cleave ataxin-2, a neurodegeneration-linked protein, variants from the redesigned BoNT/E start reached higher efficiency and stability with more than 79-fold greater selected specificity than the best wild-type evolved protease. Caveat: the workflow is still lab-scale engineering; delivery, immunogenicity, and manufacturing remain open for any therapy.